Dose selection and go/no-go decisions in a second indication by leveraging published clinical trial data for drugs/classes approved in multiple indications
Model-informed drug development with hyper accelerated time to submission - exemplified with depemokimab regulatory submissions in interleukin-5-driven diseases"